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ORAL PRESENTATIONS
O1
4.1: Nonbiopsy of presumed fibroadenomas in patients <30 years: is it
safe? A single unit experience and review of European practice
K Taylor*, H Vandersluis, P Britton, M Wallis
Cambridge Breast Unit, Cambridge University Hospitals NHS Foundation
Trust, Cambridge, UK
Breast Cancer Research 2013, 15(Suppl 1):O1
Introduction: Previous research in this centre enabled the introduction of a
local protocol of nonbiopsy and discharge of women <30 years old with
presumed fibroadenomas (FAs). Four years on, we have audited protocol
accuracy, effect on biopsy workload, safety and its potential for influencing
UK and European practice.
Methods: Women aged <30 attending the breast unit between 1 February
2009 and 31 January 2013 were retrospectively identified. Clinical and
imaging results were scored following national guidelines locally adapted to
incorporate a nonbiopsy protocol such that presumed FAs scored E2/U2
meeting specific protocol criteria were discharged without core biopsy. In
addition, a survey assessing European practice was completed by 31 centres.
Results: A total of 1,571 women age <30 were referred to the breast unit.
Seven cancers were diagnosed, all aged 25 to 29. In total, 266 presumed FAs
E2/U2, meeting nonbiopsy criteria were discharged without biopsy, 84 were
aged 25 to 29. Fourteen re-attended with increase in size, none biopsied but
five excised due to patient choice. Sixty-six E2/U2, probable FAs were
biopsied due to noncompliance with the protocol. Of these, 54 were FAs,
seven phyllodes tumours, and one cancer. The protocol resulted in a 78%
reduction in biopsy workload in women aged ≥20 and a 72% reduction in
women aged 25 to 29. No cancers developed in discharged patients, mean
follow up 2.4 years. European survey results demonstrate 29% of
respondents routinely sample FAs in women age ≥20, 55% in women age
≥25. Seventy-nine per cent of non-UK respondents follow-up FAs regardless
of patient age.
Conclusion: With rigorous adherence, our nonbiopsy protocol for
presumed FAs in women age <30 appears safe and reduces biopsy/follow-
up workload.
O2
4.2: Vacuum biopsy in the management of lobular in situ neoplasia: a
single-centre experience
C Parkin1*, S Garewal2, P Waugh2, AJ Maxwell2,3
1North Western Deanery School of Radiology, Manchester, UK; 2Royal Bolton
Hospital, Bolton, UK; 3University Hospital of South Manchester, Manchester, UK
Breast Cancer Research 2013, 15(Suppl 1):O2
Introduction: Lobular in situ neoplasia (LISN) is encountered with increasing
frequency in core needle biopsies (CNB) of the breast. It is a generalised risk
factor and probable nonobligate precursor for some breast cancers.
Historically, open biopsy was performed to exclude associated malignancy.
Controversy currently surrounds the management of LISN, and practice
consequently varies between departments. This study is a review of a single
centre’s 13-year experience of managing LISN with vacuum-assisted biopsy
(VAB) in order to assess the safety of this policy.
Methods: A retrospective review of the breast screening database,
pathology database, high-risk patient database and patients recruited to the
Sloane Project was completed. Patients with LISN as the most pertinent
diagnosis on VAB, with or without preceding 14-gauge CNB, were identified.
Those with pathological results not concordant with imaging were excluded.
The outcome of subsequent annual surveillance mammograms was
recorded.
Results: Between February 1998 and March 2012, 42 patients had LISN as
the most pertinent diagnosis at VAB, with or without preceding CNB. No
open biopsies were performed in this group. Mean radiological follow up
was 39 months (range 0 to 105 months). There were no new diagnoses of
breast cancer during follow up. Three patients died: one with a previous
history of invasive breast cancer died from metastatic breast cancer and two
died from unrelated causes.
Conclusion: In the presence of adequate tissue sampling and radiological-
pathological concordance, VAB is a safe alternative to open biopsy in the
management of LISN.
O3
4.3: Upgrades of B5a (non-invasive) core biopsies to invasive disease
at final surgery: a retrospective review across the Scottish Breast
Screening Programme
YT Sim1*, JC Litherland1,
the QA Radiology Leads, Scottish Breast Screening Programme2
1West of Scotland Breast Screening Centre, Glasgow, UK; 2Scottish Breast
Screening Programme, UK
Breast Cancer Research 2013, 15(Suppl 1):O3
Introduction: Women with B5a (non-invasive) preoperative core biopsies
upgraded to invasive disease at surgery have a high chance of needing
further surgery. The average B5a upgrade rate across UK breast screening
programmes is around 20%. Through this Scottish review, we aim to identify
factors affecting upgrade rates and ways to improve our performance.
Methods: This was a retrospective analysis of 1,252 cases of B5a biopsies
from the Scottish Breast Screening Programme between 2004 and 2012.
Final surgical pathology was correlated with radiological and biopsy factors.
Results: B5a upgrade rates for the units ranged from 19.2 to 29.2%, with
average of 23.6%. Mean sizes of invasive tumours were small (3 to 11 mm).
Upgrade rate was significantly higher for cases where the main mammo-
graphic abnormality was mass, distortion or asymmetry, compared with
microcalcification alone (33.2% vs. 21.7%) (P = 0.0004). The upgrade rate was
significantly lower with use of large-volume vacuum-assisted biopsy (VAB)
devices than 14-gauge core needles (19.9% vs. 26%) (P = 0.013). The upgrade
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rate was lower in stereotactic than ultrasound-guided biopsies (21.2% vs.
36.1%) (P < 0.001).
Heterogeneity of data from different units limited evaluation of other
potential factors.
Conclusion: There is variation in practice across Scottish units, including
first-line biopsy technique and/or device and protocols for repeat biopsy.
Upgrade rates are lower for cases with microcalcification as the sole
mammographic feature, and with use of VAB devices. Nevertheless, it is of
interest that a few centres maintain low upgrade rates despite not routinely
using VAB as the first-line technique for biopsy of microcalcification.
O5
4.5: Diagnosing breast cancer in a high-risk cohort
EAM O’Flynn1*, V Houle2, ARM Wilson2, AZ Evans3, SD Allen2
1Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK;
2Royal Marsden Hospital, London, UK; 3Ninewells Hospital and Medical
School, Dundee, UK
Breast Cancer Research 2013, 15(Suppl 1):O5
Introduction: MRI is a common method for detecting breast cancer in
women at high risk [1,2] These women may instead be diagnosed
mammographically or present symptomatically. The aim of this study was to
investigate how breast cancer is diagnosed in high-risk women and
determine whether there are specific characteristics related to the type of
presentation.
Methods: A total of 125 high-risk patients with 134 breast cancers (69 BRCA,
65 family history) were managed at the Royal Marsden Hospital from 1994
to 2013. Following ethical approval, data were collected retrospectively for
each presentation of breast cancer: method of presentation/diagnosis (MRI,
mammography, symptomatic), age at diagnosis, cancer type, grade, size,
presence of DCIS, lymphovascular invasion (LVI), nodal status and tumour
subtype. Chi-squared and ANOVA analyses determined any association
between the parameters, P < 0.05 was significant.
Results: Ten breast cancers were MRI detected, 43 mammography detected
and 81 symptomatic (mean age 41, 51, and 45 years (P = 0.008); mean size
17, 29, and 34 mm (P = 0.076) respectively).The majority of cancers were
high-grade (68%) invasive ductal carcinomas (78%) without LVI (76%). MRI-
detected cancers were triple negative in 60% (P = 0.03), node negative in
100% (P = 0.005) with DCIS in 70% (P = 0.007). Mammography-detected
cancers were luminal in 77% (P = 0.03), node negative in 77% (P = 0.005),
with DCIS in 81% (P = 0.007). Symptomatic cancers were luminal in 54%,
triple negative in 41%, node negative in 56% and DCIS positive in 51%.
Conclusion: In this high-risk cohort, MRI detects small, triple-negative,
node-negative cancers in younger women, while mammography detects
larger, luminal, cancers in older women that may be node positive.
References
1. Leach MO, et al: Lancet 2005.
2. Kuhl CK, et al: JCO 2005.
O6
4.6: Anisotropy in solid breast lesions at shear wave elastography:
relationship to the radial plane and implications for benign/malignant
differentiation
K Skerl*, S Vinnicombe, P Whelehan, K Thompson, D McLean, A Evans
University of Dundee, UK
Breast Cancer Research 2013, 15(Suppl 1):O6
Introduction: Anisotropy is the directional dependence of the measurement
of a property. As breast tissue structure and some breast diseases (DCIS) are
anisotropic in structure, we aimed to establish the frequency, degree and
diagnostic value of shear wave elastography anisotropy in solid breast
lesions.
Methods: Ninety-eight solid breast lesions (31 benign and 67 malignant)
were examined in the radial and anti-radial planes, with two mean stiffness
measurements (in kPa) being taken in each plane and averaged. The
difference between the radial and anti-radial measurements was squared to
make all readings positive, and compared with the histological diagnosis.
Paired Student t tests and chi-square tests were performed to establish
statistical significance of the relationships.
Results: Anisotropy was found in both benign and malignant lesions.
However, the stiffness values were not related to the examination plane in
either group of lesions (P = 0.2). Anisotropy was greater in malignant lesions
than benign lesions (P < 0.0001). Using a malignancy threshold value for the
square of the difference in radial and anti-radial stiffness of 200, the
sensitivity, specificity and diagnostic accuracy of the presence of this level of
anisotropy were 72%, 87% and 77% respectively.
Conclusion: Stiffness of solid breast lesions on shear wave elastography is
not directly related to the examination plane. Malignant lesions show more
anisotropy than benign lesions. Therefore, adding anisotropy to other shear
wave parameters has the potential to improve the ability of this modality to
differentiate benign from malignant solid breast lesions.
POSTER PRESENTATIONS
P1
PB.01: Second-look ultrasound examination of the breast following
MRI: MR and sonographic findings
K Alrawi*, J Bansal, P Young
Cardiff & Vale Breast Centre, University Hospital Llandough, Cardiff & Vale
University Health Board, Cardiff, UK
Breast Cancer Research 2013, 15(Suppl 1):P1
Introduction: MRI is widely accepted to be the most sensitive imaging
modality for detecting breast cancer, but has relatively low specificity.
Often additional enhancing areas are identified on MRI that require further
investigation. In this study we evaluated second-look ultrasound following
breast MRI and the impact of this on patient management.
Methods: A retrospective review was undertaken of all breast MRIs
performed between July 2010 and December 2012. Patients who had
further evaluation with second-look ultrasound were reviewed. Clinic
letters were also reviewed to identify any subsequent change in patient
management.
Results: A total of 261 breast MRI scans were performed over this time
period. Fifty-two (19.9%) had a second-look ultrasound performed; 24 for
mass-like lesions and 28 for nonmass-like lesions identified on MRI. In total,
18/24 (75%) mass-like lesions had a corresponding ultrasound abnormality,
and 12/28 (42.8%) nonmass-like lesions had a corresponding ultrasound
abnormality. Thirty biopsies were performed (57.6%) and of these nine
(17.3%) were malignant. Malignant lesions were equally distributed between
mass-like and nonmass-like lesions. In total, 7/9 malignant lesions were
scored U4 or U5, demonstrating features suspicious of malignancy.
Management was altered in all nine cases.
Conclusion: MR-directed second-look ultrasound is a valuable tool in
diagnostic work-up. Mass-like lesions on MR are more likely to have an
ultrasound correlate. Most malignant lesions had clearly malignant features
on ultrasound.
P2
PB.02: Magnetic resonance imaging axilla: friend or foe?
CF Hathaway1*, C Zammit2, S Shaheed2, G Rubin3, J O’Brien3
1Brighton and Sussex Medical School, Brighton, UK; 2Department of Surgery,
Park Centre for Breast Care, Brighton, UK; 3Department of Radiology, Park
Centre for Breast Care, Brighton, UK
Breast Cancer Research 2013, 15(Suppl 1):P2
Introduction: Breast MRI is used for local staging of breast cancer. It also
gives information on the axilla. We looked at patients whose staging breast
MRI revealed indeterminate axillary node appearances.
Methods: A retrospective analysis was conducted of all breast MRIs in one
institution between July 2012 and June 2013. MRI scans that found
indeterminate axillary nodes and recommended second-look ultrasound
were analysed, and correlated with fine-needle aspiration (FNA) cytology
and surgical histology results.
Results: A total of 180 MRI scans were performed for local breast cancer
staging, having met NICE early cancer guidelines. Ten had incomplete
follow up, leaving 170 in the study. In total, 131 correlated with the
primary axillary ultrasound imaging and cytology, and did not have
further axillary investigation. Thirty-nine (22.9%) requested second-look
ultrasounds, with 25 requiring FNA; 10 (5.9%) found positive, 15 (8.8%)
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found negative nodes. Nodes found to be positive on FNA had axillary
clearance rather than sentinel node biopsy, confirmed on surgical
histology in all 10. Of the 14 patients who did not have an FNA on
second look, only one was found to be positive on later histology. Two of
the 15 had FNA on second look, and given a negative result, did
ultimately have positive nodes on sentinel node biopsy.
Conclusion: MRI and second-look ultrasound/FNA correctly identified
10 (5.9%) more patients with involved nodes than initial staging. Twenty-
nine (17.1%) other patients had additional axillary ultrasound including FNA
in 15 (8.8%) without a change in axillary management.
P3
PB.03: Evaluating the role of breast MRI at mid-cycle chemotherapy
D Santosh1*, G Uruski1, A Borley1,2, P Young1
1Cardiff and Vale University Health Board, Cardiff, UK; 2Velindre NHS Trust,
Cardiff, UK
Breast Cancer Research 2013, 15(Suppl 1):P3
Introduction: The aim was to evaluate whether breast magnetic resonance
imaging (MRI) following mid-cycle chemotherapy was influencing the
neoadjuvant chemotherapy (NAC) regimen.
Method: Thirty-two patients with breast malignancy receiving NAC were
included in this retrospective study. Baseline and mid-cycle MRI were
performed. NAC regimen and breast MRI reports were obtained from an
online database. Tumour response was assessed by calculating percentage
of volume reduction between interval scans. The response was categorised
arbitrarily as good, moderate and poor with >50%, 20 to 50% and <20%
reduction in tumour volumes respectively.
Results: Nine patients had second tumours detected on the baseline MRI.
The index tumours (n = 32) had showed good response in 23 (71.9%),
moderate response in four (12.5%) and poor response in five (15.6%) on
their mid-chemotherapy MRI. The five poor responders had good response
in either the axillary node or in the second tumour. The second tumours
(n = 9) showed good response in six (66.7%), moderate in two (22.2%) and
poor in one (11.1%). No changes were made to chemotherapy regimen
based on the MRI findings and these percentage tumour volume
reductions.
Conclusion: Our study shows that the percentage reduction in the tumour
volumes demonstrated by the interval MRI scans are an important
determinant of response to NAC. It is possible to obtain similar information
from newer 4D sonography, which is cheaper and quicker to perform than
MRI, and is better tolerated. In our practice, assessment at the mid-
chemotherapy point is now undertaken with clinical assessment and
ultrasound, which have provided adequate information regarding tumour
responses to chemotherapy.
P4
PB.04: MRI In lobular and mixed lobular/ductal carcinomas: can we
preselect cases based on imaging appearance?
MM Hoosein*, L Grosvenor, D Lister, M Al-Attar
University Hospitals of Leicester, UK
Breast Cancer Research 2013, 15(Suppl 1):P4
Introduction: Lobular carcinoma presents a diagnostic challenge. Imaging
and clinical findings are usually subtle. In the current climate it imposes extra
strain on our resources. Our aim was to assess contribution of MRI in the
preoperative local staging of lobular and mixed lobular/ductal carcinoma and
to evaluate whether we can select cases for preoperative MRI based on
mammographic appearance.
Methods: A retrospective review of data provided by the local breast
cancer database was performed. Patients with confirmed lobular or mixed
lobular/ductal carcinomas that had MRI staging during a 5-year period were
identified. Imaging and histopathology reports were reviewed. A total of 381
cancers were diagnosed in the study period. Ninety-one patients had breast
MRI. Four cases were excluded as no final histology was available. Eighty-
seven patients (mean age 58) with 89 involved breasts constituted our study
population.
Results: Breakdown of mammographic lesions was as follows: PD, 39
(43.8%); masses, 20 (22.4%); ASD, 18 (20.2%); lymphoedema, one (1.1%);
calcifications, two (2.2%); occult/subtle, nine (10.1%). MRI had a positive
contribution in 27/83 cases (32.5%), did not add any further information in
49/83 cases (59%) and a negative contribution in only 7/83 cases (8.4%). MRI
notably identified greater disease extent, multifocal and contralateral
disease. MRI was most useful in assessing disease extent when lobular
carcinoma presented as PD or mammographically occult and was of least
benefit when presenting as a mass lesion.
Conclusion: MRI had no advantage over conventional imaging in the
majority of lobular and mixed lobular/ductal cancers presenting as a focal
mass lesion. Its application could be tailored more specifically to assess
nonmass lesions.
P5
PB.05: MRI-guided vacuum-assisted breast biopsy at 3T: initial
experience
M Sreenivas
University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK
Breast Cancer Research 2013, 15(Suppl 1):P5
Introduction: As the specificity is relatively low, histological confirmation of
incidental breast lesions at 3T is needed if the treatment plan has to change.
MRI-guided biopsy is needed as a proportion of these lesions will not been
seen on conventional imaging.
Methods: Forty-nine out of 240 patients undergoing DCE-MRI studies
performed between 1 July 2011 and 20 July 2013 warranted second-look US
(20% of patients). Fifteen of the 49 patients underwent MRI-guided biopsy
predominantly as second-look US was negative. Diagnostic imaging and
biopsy were performed on GE 3T using a dedicated breast coil, grid method,
CADstream software and Vacora vacuum-assisted biopsy device with a 10G
needle obtaining between 10 and 22 cores.
Results: Fourteen of the 15 patients had technical success (in one patient
the biopsy had to be performed twice due to unsatisfactory sampling, and
repeat biopsy yielded B5b).
Seven nonmass M3 lesions yielded a 43% malignancy rate (B4 = 1 and
B5a = 2). Two of five M4 lesions were masses yielding B5a with overall
malignancy yield in this category of 40%. One of the two M5 masses was
B5b with a cancer yield in this category of 50%. Overall malignancy yield
was 43%.
Conclusion: As far as we know we are the only unit in the UK to perform
MRI-guided breast biopsy at 3T and our results are in accordance with
published literature (cancer yield between 24 and 40%). This preliminary
work has shown that MRI biopsy at 3T is feasible using a hand-held
multiple-insertion vacuum-assisted device.
P6
PB.06: Preliminary results in the performance comparison between the
size ratio and colour scoring breast ultrasound elastographic
techniques
LCH Leong*, THL Moey, LSJ Sim
Singapore General Hospital, Singapore
Breast Cancer Research 2013, 15(Suppl 1):P6
Introduction: There are a few breast ultrasound elastographic techniques
that can help with distinguishing malignant breast lesions from benign
ones. Two of the better known ones are the size ratio and colour scoring
methods. The aim of this study is to prospectively compare the diagnostic
performance of these two elastographic techniques.
Methods: Female patients referred to the radiology department for image-
guided breast biopsy were prospectively evaluated with ultrasound
elastography prior to biopsy following informed consent. The two
elastographic methods were assessed on each breast lesion separately by
different radiologists. A size ratio of ≥1.1 was taken to be malignant and
<1.1 was benign. Colour scores of 1 to 3 were taken as benign and colour
scores of 4 to 5 were considered malignant. Histological diagnosis was
used as the gold standard. The sensitivity and specificity of both
techniques were compared using the Fisher’s exact test.
Results: Sixty-five breast lesions in 63 women were evaluated at the interim
stage of the study. There were 21 malignant and 44 benign breast lesions.
The sensitivity and specificity of the size ratio technique were 100% (21/21)
and 81.8% (36/44). The sensitivity and specificity of the colour scoring
method were 57.1% (12/21, P = 0.001) and 86.4% (38/44, P = 0.772).
Breast Cancer Research 2013, Volume 15 Suppl 1
http://breast-cancer-research.com/supplements/15/S1
Page 3 of 15
Conclusion: The preliminary results indicate that the size ratio
elastographic technique is more sensitive and accurate than the colour
scoring method. A larger study is ongoing.
P7
PB.07: Why are some fibroadenomas stiff using shear wave
elastography?
M Elseedawy3*, P Whelehan1,2,3, S Vinnicombe1,2,3, K Thomson1,2,3, A Evans1,2,3
1Dundee Cancer Centre, Dundee, UK; 2Ninewells Hospital, Dundee, UK;
3University of Dundee, UK
Breast Cancer Research 2013, 15(Suppl 1):P7
Introduction: Shear wave elastography (SWE) is a promising modality for
differentiating benign from malignant breast masses. A proportion of
fibroadenomas are stiff (mean stiffness >50 kPa), resulting in false positive
SWE findings. The aim of this study was to identify which features of
fibroadenomas are associated with false positive SWE findings.
Methods: A total of 151 patients with histologically confirmed fibro-
adenomata were identified from a prospective database, from a single
breast unit. The following features were assessed by a single observer who
was unaware of the SWE findings: Patient age, greyscale ultrasound lesion
diameter (<15 mm or ≥15 mm), distance from the lesion to skin,
composition of surrounding tissue (fatty, mixed or dense) and source of
referral (screening or symptomatic). Statistical analysis was carried out using
the chi-square test.
Results: A statistically significant association was found between greyscale
ultrasound lesion size and lesional stiffness. Twenty-nine of 70 (41%) lesions
≥15 mm were stiff, versus 10 of 81 (12%) <15 mm, P = 0.001. Patient age,
distance from the lesion to skin, makeup of surrounding tissue and source
were not significantly associated with stiffness.
Conclusion: Fibroadenomas giving false positive SWE results tend to be
larger in size than these that do not. More compression of adjacent normal
tissue is assumed to be the cause of our findings. As previous studies have
shown that large cancers tend to be stiffer than smaller cancers, it may be
appropriate to vary the quantitative cutoff value used for benign/malignant
differentiation in SWE according to lesion size.
P9
PB.09: Clinical audit of technical recall data for blur following the
introduction of the breath hold technique in breast screening
LE Bisset
Dorset Breast Screening Unit, Poole, UK
Breast Cancer Research 2013, 15(Suppl 1):P9
Introduction: Digital mammography has increased the number of
technical recall (TR) appointments due to blurred images. Within a regional
breast screening unit, 177/29,314 women (0.6%) were recalled in an
analogue 12-month period compared with 639/30,102 (2.12%) with digital.
Current NHSBSP TR standard = 3%, target = 2% [1]. A retrospective audit
to assess breath-hold technique TR data aimed to: measure and record
data for the TR’s pre and post breath hold; compare these results with
NHSBSP standards; and make recommendations for future practice based
on these results.
Methods: Datasets gathered information that included mammographic
view, radiographer, side of blur, compressed breast thickness, force and
location. The data for the pre breath hold sample (8,467) and post breath
hold sample (9,072) were compared. A retrospective questionnaire of
mammographers’ perceptions demonstrated the technique was easy and
rarely added additional time.
Results: Pre breath hold there were 104/8,467 recalls for blurring, and post
breath hold there were 31/9,072. The results demonstrate recalls measured
against the NHSBSP targets, and TRs dropped from 3.21% (above
recommended practice) to 2.08% (in line with standard/almost target
recommendations). This is a 69.1% reduction. Fisher’s exact test and
Pearson’s chi-squared with Yates’ continuity both produced P < 2.2 × 10-16.
Both were therefore statistically significant for blur.
Conclusion: The breath hold technique has reduced the number of TRs for
blur. Therefore, it is recommended that this technique should be adopted
across the entire NHSBSP.
Reference
1. NHSBSP: Consolidated Guidance on Standards for the NHSBSP Sheffield: NHS
Cancer Screening Programmes 2005, Publication Number 60.
P10
PB.10: Breast compression, compressed breast thickness and
volumetric breast density
J Khan-Perez1*, C Mercer2, M Bydder2, J Sergeant3, J Morris4, A Maxwell2,
C Rylance2, S Astley3
1The University of Manchester Medical School, Manchester, UK; 2Nightingale
Breast Centre and Genesis Prevention Centre, UHSM, Manchester, UK;
3Centre for Imaging Sciences, Institute of Population Health, University of
Manchester, UK; 4Department of Medical Statistics, University Hospital of
South Manchester, Wythenshawe Hospital, Manchester, UK
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Introduction: Adequate compression of the breast during mammography
is essential both for ensuring high-quality images and for accurate
assessment of breast density using automated volumetric breast density
software. Here we explore the relationship between breast density and
imaging parameters.
Method: We identified a set of 210 women undergoing routine screening
mammography by the same experienced radiographer using the same
mammography unit. Breast density data (breast volume, fibroglandular
tissue volume) were obtained using Volpara™ 1.4.0 and imaging parameters
(compression force, breast thickness and dose) were extracted from the
DICOM headers. Statistical analysis using Spearman’s rank-order coefficient
was used to examine any existing relationships.
Results: There were significant positive correlations (P < 0.01) between
both breast volume and gland volume with compressed breast thickness,
X-ray dose and compression force (P < 0.05). Volumetric breast density was
negatively correlated with compression force in the CC view (P < 0.01) and
thickness in all views (P < 0.01), and breast volume had a significant
positive correlation with gland volume (P < 0.01).
Conclusion: Our results show that large, dense breasts had greater
thicknesses, higher X-ray doses and required a greater compression force
during mammography. There was insufficient evidence to determine
whether higher compression forces in larger breasts were due to increased
glandular content. The negative correlations with volumetric breast density
expressed as the percentage of the breast volume occupied by dense
fibroglandular tissue can be explained by the fact that the positive
correlations with breast volume were stronger than those with gland
volume.
P11
PB.11: Identifying women at high risk of developing breast cancer:
implications of adjusting for inter-observer variability in visual
analogue scale assessment of percentage breast density
JC Sergeant1*, M Sperrin2, L Bardwell3, I Buchan2, DG Evans4, A Howell4,
SM Astley1
1Centre for Imaging Sciences, Institute of Population Health, University of
Manchester, UK; 2Centre for Health Informatics, Institute of Population
Health, University of Manchester, UK; 3Department of Mathematics and
Statistics, University of Lancaster, UK; 4Nightingale Centre and Genesis
Prevention Centre, University Hospital of South Manchester, UK
Breast Cancer Research 2013, 15(Suppl 1):P11
Introduction: Breast density is a well-established risk factor for breast
cancer, with assessment of percentage density via a visual analogue scale
(VAS) a practical method of measurement strongly associated with risk. We
present a method to adjust for inter-observer differences in VAS density
estimates and examine the effect of adjustment on the classification of
women at high risk of developing breast cancer.
Methods: A two-stage method is used to make estimates by different
observers comparable. Results from all observers are transformed onto the
same distribution, then differences in case mix are accounted for. We
applied our approach to 13 experienced readers assessing 13,694 screening
mammograms from a large clinical study where women are categorised as
high risk if they have a 5 to 8% 10-year risk computed by a validated risk
model and their breast density is in the top decile of the study population.
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Results: A total of 1,125 women were assessed as having a 10-year risk
of 5 to 8%. Initially 126 of these were also high density, therefore
classified as high risk, rising to 147 after density adjustment. After
adjustment, 35 women were reclassified from nonhigh to high risk (3.5%
of those initially nonhigh risk) and 14 women were reclassified from high
to nonhigh risk (11.1% of those initially high risk).
Conclusion: Adjusting VAS estimates of breast density for inter-observer
variation substantially affected which women were classified as high risk
of developing breast cancer. If VAS assessment of density is to be used in
risk assessment to inform screening strategies, adjustment must be
considered.
P13
PB.13: Comparison between analogue and digital mammography: a
reader’s perspective
H Gay*, R Pietrosanu, S George, D Tzias, R Mehta, C Patel, S Heller, L Wilkinson
St George’s Hospital NHS Trust, London, UK
Breast Cancer Research 2013, 15(Suppl 1):P13
Introduction: In comparison with analogue film, digital mammography
provides images with more contrast and allows image manipulation. This
study compares features identified on digital and analogue mammograms.
Methods: During the transition to digital mammography between June and
August 2011, women who had received analogue screening mammography
and required further views at assessment had repeat digital images. Eight
readers reviewed digital and analogue images separately, marking all
features that caught their attention on a pro forma. Readers commented on
breast density and characterised all features using BiRads descriptors.
Results: Twenty-three women were recalled for soft tissue lesions (six
malignancies) and 13 for calcifications (one malignancy). Fifty analogue/
digital single-view mammogram pairs were obtained, 11 included
histologically malignant abnormalities. Breast density scores were lower on
digital than analogue (P < 0.001). There was no significant difference in the
descriptions of calcifications. More inconsequential soft tissue features were
described on analogue. Soft tissue features tended to be scored as less
conspicuous on analogue than digital images. There was no significant
difference in the description of 5/6 soft tissue cancers, but one cancer was
seen by five readers on analogue, and only two on digital mammogram. See
Table 1.
Conclusion: This study showed that readers reported breasts as less dense
and identified fewer distracting soft tissue lesions on digital mammography
but there was no difference in the reporting of calcifications. One of six
cancers was under-reported on digital mammography.
P14
PB.14: Visibility of screen-detected invasive carcinoma on digital breast
tomosynthesis: do we need two views?
O Abeyakoon*, D Evans, R Rahim, J Morel, R Wasan, A Iqbal, J Golligher,
C Peacock, M Michell
Kings College Hospital, London, UK
Breast Cancer Research 2013, 15(Suppl 1):P14
Introduction: Digital breast tomosynthesis (DBT) increases the sensitivity
and specificity of detecting invasive breast carcinoma. Integration into
screening raises questions. Should we perform two-view full-field digital
mammography (FFDM) and two-view DBT or two-view FFDM and single-
view DBT at every screening? DBT is shown to offer greatest benefit in the
assessment of a soft tissue lesion. We routinely use two-view DBT in
combination mode for all patients recalled from screening for a soft tissue
abnormality. The aim of our study is to assess the need for two-view DBT in
the detection of breast cancer.
Methods: We retrospectively queried our histopathology database for all
screen-detected invasive cancers between 2011 and 2012. The study
sample was 254 cases. Comparisons were made between the visibility of
the cancer on MLO/CC DBT and histological type/grade, molecular profile
and breast density (BIRADS).
Results: The mean age was 59 years. In total, 4/254 cancers were visible on
one-view DBT (1.6%). (Two seen on MLO DBT [spiculated masses] and two
seen only on the CC view [distortions]). A total of 11/254 had greater
visibility on one view in comparison with the other view on DBT (4.3%). Two
of 254 cases were occult on FFDM and DBT. Recall was for clinical
symptoms, both lobular invasive carcinoma (0.79%). There was no
relationship between histological type, grade or molecular characteristics
and the visibility on one-view versus two-view DBT.
Conclusion: A total 98.4% of cancers were seen on two-view FFDM and
MLO-DBT. Integration of MLO-DBT into breast cancer screening with two-
view FFDM is a consideration.
P15
PB.15: Pain in mammography: where and why does it arise?
D O’Leary*, Z Al Maskari
University College Dublin, Ireland
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Background: The purpose of the study was to determine the intensity of
pain experienced by women undergoing mammography examination
through investigation of biological, psychological and technical factors that
influence any pain felt during the examination.
Methods: Sixty-four women presenting for diagnostic and screening
mammography were examined. Pain experience data were collected at
three discrete time-points during mammography using both a visual
analogue and Likert scales.
Results: Pain due to compression was rated by 96.6% of women. The
pain/discomfort averaged between mild (42%) to moderate (49%) in the
craniocaudal (CC) projection and between mild (22%), moderate (61%) to
very severe pain (13.5%) in the mediolateral oblique (MLO) projection.
Correlation identified significant associated factors for pain: women’s age
(P = 0.001), menstruation (P = 0.042), menopausal status (P = 0.002) and
marital status (P = 0.000). A unique aspect was the investigation of the
sources of pain in each projection. Pain experienced during breast
compression mainly arises from compression pressing on the middle of
the breast and chest wall in the CC and from the compression pressing
on the sternum, middle and underside of the breast and the axilla in
the MLO.
Conclusion: This study supports other published work that women
experience pain during breast compression within mammography and
that the radiographer plays a major role in the women’s experience of
pain. The study contributes to the pain debate by showing where the
pain arises in the breast specifically during compression and the degrees
of pain felt.
P16
PB.16: Contrast-enhanced digital mammography: a single-centre
experience
SB O’Neill*, DC O’Neill, N Marshall, L Duddy, MF Ryan, JE Barry
Cork University Hospital, Cork, Ireland
Breast Cancer Research 2013, 15(Suppl 1):P16
Introduction: Contrast-enhanced mammography is a relatively novel
technique. We describe a single-centre experience with use of the technique
to facilitate the detection and characterisation of lesions in the breast by
triangulation of contrast-enhanced mammography, biopsy/gross
pathological specimen and MR findings.
Methods: Retrospective review of the pathological and imaging findings of
consecutive patients undergoing contrast mammography was performed.
Sixty-four contrast mammograms were performed on 61 patients (all female,
mean age 54.3 ± 13.2 years) over a 15-month period. Technique involves a
dual energy acquisition of CC and MLO views following the administration
of contrast medium, then digital subtraction (GE Senographe DS).
Results: At contrast-enhanced digital mammography, enhancement was
observed in 37 of 43 patients with biopsy-proved cancers. Of the six patients
Table 1(abstract P13) Aggregate features identified
(number of times features were marked)
Analogue Digital
Soft tissue 398 319
Calcifications 178 173
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with a cancer diagnosis but no enhancement, three were post neoadjuvant
treatment. Three patients without a tissue diagnosis of malignancy
demonstrated mammographic enhancement. Fourteen patients also
underwent gadolinium-enhanced breast MR. Nine out of 10 patients
with MR enhancement also demonstrated enhancement on contrast
mammogram. One patient with no MRI enhancement had enhancement on
contrast mammography. Morphology generally correlated with the
pathologic diagnosis.
Conclusion: The results of this study demonstrate the utility of contrast-
enhanced mammography in the identification, evaluation and follow-up of
breast lesions. It offers similar enhancement characteristics to MRI and
represents a feasible alternative in centres without onsite MRI.
P17
PB.17: Inter-observer agreement in visual analogue scale assessment of
percentage breast density
JC Sergeant1*, M Wilson2, N Barr2, U Beetles2, C Boggis2, S Bundred2,
M Bydder2, S Gadde2, E Hurley2, A Jain2, Y Lim2, L Lord2, V Reece2, DG Evans2,
A Howell2, SM Astley1
1Centre for Imaging Sciences, Institute of Population Health, University of
Manchester, UK; 2Nightingale Centre and Genesis Prevention Centre,
University Hospital of South Manchester, UK
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Introduction: Breast density is an important risk factor for breast cancer.
Assessment of density at screening could help identify women at increased
risk of cancer, who may benefit from screening with shorter intervals or
different modalities. Visual analogue scale (VAS) assessment of percentage
density by observers is straightforward to implement and strongly
associated with cancer risk. However, using VAS assessment for stratification
would require reproducibility between observers. We examine agreement
between observers assessing VAS density.
Methods: The VAS breast density of 120 screening cases with full-field
digital mammograms was independently assessed by 12 experienced
mammographic readers. The agreement between the readers was assessed
using Bland-Altman limits of agreement and the concordance correlation
coefficient (CCC). The VAS densities were also converted to BIRADS breast
composition categories and agreement measured with Cohen’s weighted
kappa.
Results: The greatest difference between two estimates for the same case
was 67.75 percentage points, while the mean difference between reader
pairs ranged from 0.76 to 28.58 percentage points. The 95% limits of
agreement between reader pairs were (-6.96, 18.62) at their narrowest and
(-59.13, 1.97) at their widest. Pairwise CCC values ranged from 0.44 to 0.92,
while the overall CCC was 0.70. Pairwise kappa values for the BIRADS
classification ranged from 0.37 to 0.84, with a mean of 0.66.
Conclusion: Substantial lack of agreement was found between readers
visually assessing percentage breast density. This study demonstrates the
need for reader harmonisation, either by training or by adjustment of
results, should VAS density assessment be used for risk stratification.
P18
PB.18: Factors affecting breast density assessment
L Beattie1*, M Bydder2, JC Sergeant3, A Maxwell2, N Barr2, U Beetles2,
CRM Boggis2, S Bundred2, S Gadde2, E Hurley2, A Jain2, E Lord2, V Reece2,
M Wilson2, P Stavrinos2, DG Evans2,4, A Howell2,5, SM Astley2,3
1University of Manchester Medical School, Manchester, UK; 2Nightingale
Centre and Genesis Prevention Centre, University Hospital of South
Manchester, UK; 3Centre for Imaging Sciences, University of Manchester, UK;
4Department of Genetics, St Mary’s Hospital, Manchester, UK; 5Institute of
Cancer Sciences, University of Manchester, UK
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Introduction: High breast density, where there is a relatively large
proportion of fibroglandular tissue in the breast, is associated with increased
risk of developing cancer. There are several methods of assessing breast
density from mammograms, and as these sometimes disagree about
whether density is high (or low), we have investigated potential causes of
disagreement.
Methods: A set of 6,422 mammograms with density assessed visually by
two readers using Visual Analogue Scales, and volumetric breast density
measured using Quantra™ and Volpara™ was obtained from the PROCAS
(Predicting Risk Of Cancer At Screening) database. Cases were ranked
from the highest to lowest density by each method. For each pair of
methods the 20 cases with the largest discrepancy in rank, and the 20
with the smallest, were selected. Image features were recorded and
compared.
Results: The two volumetric methods were more likely to disagree when
calcification was present and the inframammary fold was poorly
positioned. When comparing Quantra™ to visual assessment, there were
more skin folds and a higher compressed breast thickness in the
discrepant cases. Comparing Volpara™ with visual assessment, there were
more suboptimal inframammary folds and higher compression forces in
the discrepant group.
Conclusion: Although visual and volumetric methods are unlikely to
produce similar density estimates, those ranked highly by one method
should correspond to the high-density cases identified by another. Our
study indicates the need for further investigation, as lack of ground truth
means that in cases of disagreement it is not possible to tell which method
produced better density estimates.
P19
PB.19: Investigation of a novel method for breast discomfort reduction
during mammography
D O’Leary*, Z Al Maskari
University College Dublin, Ireland
Breast Cancer Research 2013, 15(Suppl 1):P19
Introduction: The purpose was to determine the effectiveness of a silicon
cushion in providing pain relief during mammography when used to cover
sharp edges on the image receptor and/or compression paddle. The impact
of the silicon pad(s) on image quality and radiation dose was assessed.
Methods: The transparent silicon pad was randomly assigned to the right/
left breast of the patient; the other breast was imaged as normal. The pad
(s) was strategically placed on the mammography machine using three
methods. Pain experience data were collected at three discrete time-points
during mammography using a visual analogue and Likert scales.
Radiologist image evaluators were blinded to pad assignment for image
quality evaluation. Radiation dose to the breast was compared with the
pad and without.
Results: Quantitatively, no significant reduction (P > 0.05) was observed in
the pain experienced due to the silicon pad in either mammographic
projection. Qualitatively, there was a trend for pain reduction with the
silicon pad. No statistically significant degradation in image quality was
assessed in either projection except due to the pad design. There were,
however, significant increases in the radiation dose (P < 0.00) for both
projections due to the slight increase in the compressed breast thickness
due to pad thickness.
Conclusion: The silicon breast cushion requires significant design changes
before commercial use for pain reduction intervention in mammography.
The study did, however, emphasise that the radiographer plays an
important role in the women’s experience and communication by the
radiographer helps in qualitatively reducing the women’s experience of pain
during the examination.
P20
PB.20: Accuracy of specimen radiograph in determining lesion
presence in excised specimens, correlating histological and
radiological margins
L Sundaram*, N Hartley, M Hoosein, M Al-Attar, E Denton, L Grosvenor,
D Lister, G McDonald, S Kaneri
Breast Care Centre, Glenfield Hospital, UHL, Leicester, UK
Breast Cancer Research 2013, 15(Suppl 1):P20
Introduction: Radiography of the excised specimen post localisation
determines whether the target lesion has been removed [1]. The surgical
specimen is oriented and if a margin appears suspicious on imaging, further
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tissue is removed [2]. An incompletely excised carcinoma adds to further
surgical workload, psychological and physical morbidity for patients.
Methods: All patients with biopsy-proven carcinoma undergoing
therapeutic excision over a 16-month period were reviewed. A retrospective
review of the mammographic lesion localised, visualisation on specimen
radiograph (SR), SR report on adequacy, margins of excision, histology of
tumour, margins after WLE and further surgery (including minimum
distances on margins) was performed and recorded.
Results: Of 68 therapeutic wire-guided excisions, lesion was accurately
detected in SR in 67/68 cases (99%), comparable with the published
literature. In 53/68, no more excision was recommended on imaging. Of
these, histology confirmed clear margins in 45/68. Further immediate
excision was correctly advised in 15 patients. New excision margins were
clear in 10/15 cases, thus avoiding second surgery for this subgroup.
Extensive disease was seen despite re-excision in five patients. Accuracy of
commenting on tumour at margins was 60/68 (88%).
Conclusion: Discrepancy between radiological and histological margins
has significant implications. Accurate SR interpretation is vital. Meticulous
attention to the protocol will reduce errors.
References
1. Quality Assurance Guidelines in Breast Cancer Screening NHSBSP Publication
Number 20. Sheffield: NHS Cancer Screening Programmes, 3 2003.
2. White J, et al: Compliance with breast conservation standards for
patients with early breast carcinoma. Cancer 2003, 97:893-904.
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PB.21: Relationship between volumetric breast density and
socioeconomic status
L Samuels1*, SM Astley1, A Maxwell2, JC Sergeant1, J Morris3, M Wilson2,
P Stavrinos2, DG Evans2, A Howell2, M Bydder2
1University of Manchester, UK; 2Nightingale Centre and Genesis Prevention
Centre, University Hospital of South Manchester, UK; 3University Hospital of
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Introduction: Women of higher socioeconomic status (SES) are at increased
risk of developing breast cancer, but it is unclear to what extent this is
mediated by differences in mammographic breast density, a well-
established breast cancer risk factor. Here we explore the relationship
between volumetric breast density and SES.
Methods: Data from 6,398 perimenopausal/postmenopausal women
undergoing routine NHSBSP screening were obtained from those consenting
to the PROCAS (Predicting Risk Of Cancer At Screening) study. SES was
assessed by obtaining the Index of Multiple Deprivation (IMD) associated
with each participant’s postcode. Volumetric breast density was measured
using Volpara™. The association between volumetric breast density and IMD,
adjusting for age, HRT use and BMI, was assessed using linear regression.
Results: A very weak negative relationship was seen between volumetric
breast density and IMD (B coefficient -0.023, P < 0.001), suggesting that
increasing deprivation (lower SES) is associated with reduced breast
density. A decreasing trend in IMD was seen with Volpara™ VDG breast
density category (Table 1). This relationship was mainly driven by a
negative association between SES and BMI, although unaffected by age
or current HRT use.
Conclusion: SES (as measured by IMD) is not strongly associated with breast
density. Established SES gradients in breast cancer risk are likely to be related
to other SES-related factors, primarily BMI, rather than mammographic breast
density.
P22
PB.22: Does the Nottingham predictor of bidimensional product of
calcium accurately predict the success of wide local excision for
ductal carcinoma in situ surgery in our centre?
R Gray*, G Porter, J Steel
Plymouth Hospitals NHS Trust, Plymouth, UK
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Introduction: A 2007 Nottingham paper suggests that a mammographic
bidimensional product (BDP) of <800 mm2 calcification in high-grade ductal
carcinoma in situ (DCIS) and <400 mm2 in low/intermediate DCIS is a
powerful predictor of successful excision. We wanted to see whether their
results were reproducible at our centre.
Methods: Eighty-four consecutive cases of DCIS over 18 months were
reviewed and examined to determine the BDP of calcium (extent of
mammographic calcification was measured in two orthogonal planes on the
oblique view). Was reoperation required? Does the pathology report show
clear margins? We excluded 15 patients that had a mastectomy (18%).
Results: See Table 1.
Conclusion: We did not obtain similar results to the Nottingham paper. The
success rate of WLE for low-grade DCIS was not (significantly) affected by
BDP. Had BDP led to a recommendation not to perform WLE, the majority
(75%) of women in this low-risk group, most at risk of overtreatment, would
have had a mastectomy when conservative surgery would have succeeded.
While we have not the large numbers of the Nottingham paper, we feel that
in our centre at least, BDP of calcification seems not to be a practically
useful predictor of excision success in nonhigh-grade DCIS.
P23
PB.23: Effect of detector type on cancer detection in digital
mammography
A Mackenzie1,2*, LM Warren1,2, DR Dance1,2, J Cooke3, M Halling-Brown4,
P Looney1, DP Chakraborty5, MG Wallis6,7, RM Given-Wilson8, KC Young1,2
1National Co-ordinating Centre for the Physics of Mammography, Royal Surrey
County Hospital NHS Foundation Trust, Guildford, UK; 2Department of Physics,
University of Surrey, Guildford, UK; 3Jarvis Breast Screening and Diagnostic
Centre, Guildford, UK; 4Scientific Computing, Medical Physics, Royal Surrey
County Hospital NHS Foundation Trust, Guildford, UK; 5Department of
Radiology, University of Pittsburgh, PA, USA; 6Cambridge Breast Unit,
Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; 7NIHR
Cambridge Biomedical Research Centre, Cambridge, UK; 8Department of
Radiology, St George’s Healthcare NHS Trust, London, UK
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Introduction: This work measured the effect that image quality associated
with different detectors has on cancer detection in mammography using a
novel method for changing the appearance of images.
Methods: A set of 270 mammography cases (one view, both breasts)
was acquired using five Hologic Selenias and two Hologic Dimensions
X-ray units: 80 normal, 80 with simulated inserted subtle calcification
clusters, 80 with subtle real noncalcification malignant lesions and 30
with benign lesions (biopsy proven). These 270 cases (Arm 1) were
converted to appear as if they had been acquired on two other imaging
systems: needle image plate computed radiography (CR) (Arm 2) and
powder phosphor CR (Arm 3). Three experienced mammography
readers marked the location of suspected cancers in the images and
Table 1(abstract P21)
Volpara™ density
grade (VDG)
Volpara™ breast
density (%)
Mean
IMD
Number (%) of
women
1 <4.5 28.8 1923 (30.0%)
2 4.5 to 7.5 26.2 2765 (43.2%)
3 7.6 to 15.5 24.4 1505 (23.5%)
4 >15.5 21.4 205 (3.2%)
Table 1(abstract P22)
BDP Successful WLE Margins not clear
High-grade DCIS
<800 mm2 15, 60% (Nottingham 69%) 10
>800 mm2 2, 50% (Nottingham 24%) 2
Low-grade DCIS
<400 mm2 24, 86% (Nottingham 73%) 4
>400 mm2 9, 75% (Nottingham 33%) 3
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classified whether each lesion would require further investigation and
the confidence in that decision. Performance was calculated as the area
under curve (AUC) of the alternative free-response receiver operating
characteristic curve.
Results: The AUCs of Arms 1 to 3 were 0.750, 0.707 and 0.648 for
calcification clusters and 0.744, 0.722 and 0.694 for noncalcification cancers.
The differences between all of the arms for calcification clusters were
statistically significant (P < 0.05). No significant differences were found for
noncalcification lesions. The percentage of correctly marked lesions that
were classified as recalled lesions dropped from 58% to 39% (calcifications)
and from 72% to 62% (non-calcifications) between Arms 1 and 3.
Conclusion: Detector type has a significant impact on the detection and
recall of calcification clusters but not noncalcification cancers.
P24
PB.24: Is digital breast tomosynthesis helpful within a symptomatic
one-stop breast clinic for characterisation of subtle findings?
GJ Bansal*, P Young, K Lim, Z Rees
University Hospital of Llandough, UK
Breast Cancer Research 2013, 15(Suppl 1):P24
Introduction: The study investigated the accuracy of two-view full-field
digital (2D) mammograms (FFDM) by comparing its performance with two-
view digital breast tomosynthesis (3D) plus FFDM combination in a
symptomatic setting.
Methods: A multi-case multi-reader study was conducted involving four
imagers of varying experience. A total of 109 lesions from 103 patients who
attended symptomatic breast clinics during a 7-month period between
March 2012 and September 2012 were retrospectively read. All patients who
had subtle signs on 2D images were retrospectively double read in a free
response study and the findings recorded. The performance quality of the
methods was evaluated using receiver operating characteristic (ROC) curves.
Reader agreement (k values) was calculated and the area under curve (AUC)
was compared between 2D imaging and 2D+3D imaging, regarding both
readers and cases as random events.
Results: There was more inter-reader agreement between the two readers
with 2D+3D combination (k = 0.391) compared with 2D images alone (k =
0.153). In total, 85.19% of M3 mammograms on 2D imaging were changed
to 11.01% M3 and 77.06% M2 on combination of FFDM and DBT. There was
more correlation between the mammographic scores and the final result for
combination mode compared with 2D images alone (P = 0.0001). ROC
analysis revealed the AUC for the combination (0.898) was significantly
greater than 2D mammograms alone (0.734; P = 0.009).
Conclusion: DBT increases diagnostic sensitivity in a symptomatic setting
and reduces the number of M3 mammograms, when used as an adjuvant to
2D images. Thus DBT has the potential of increasing work-flow efficiency in
a symptomatic setting by reducing benign biopsies.
P25
PB.25: Relationship between volumetric breast density, age and
hormonal factors
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Introduction: Percentage breast density estimated visually or assessed by
computer-assisted area-based measures declines with age, menopausal
status and parity and increases with current HRT use. Automated volumetric
density measurement methods including Quantra™ and Volpara™ remove
subjectivity; it is important to determine how these methods relate to age
and endocrine changes and here we describe these associations.
Methods: Women undergoing routine screening in the NHSBSP who
agreed to enter the Predicting Risk Of Cancer At Screening (PROCAS) study
completed questionnaires concerning personal information. Percentage
volumetric breast density was measured using Quantra™ (21,370 women)
and Volpara™ (11,023 women), and WAS related to age and hormonal
factors.
Results: Density significantly declined with age (P < 0.001) by both methods.
In women aged <50 the mean density by Quantra™ was 19.23 for
premenopausal and 16.29 for postmenopausal women (P < 0.05), and in
women aged 51 to 55 years these figures were 18.06 and 15.72 (P < 0.05). For
density measured by Volpara™, the corresponding figures are 7.74 and 6.64
(P < 0.05) for women aged <50, and 7.54 and 6.00 (P < 0.05) for women aged
51 to 55. Current HRT use was associated with significantly higher density
(P < 0.05) for those aged over 50 (Volpara™) and from 51 to 70 (Quantra™).
Nulliparity was associated with higher breast density at all ages (P < 0.05 for
Quantra™ above the age of 50 and for Volpara™ from age 51 to 65).
Conclusion: These data indicate that percentage density by both
volumetric methods is related to age and endocrine factors in the same
directions as area-based methods. It is now important to determine their
relationship to risk of developing cancer.
P26
PB.26: Significance of flat epithelial atypia at image guided breast
biopsy
S Dani*, S Sudderuddin, G Ralleigh, N Zaman, A Gupta, N Barrett,
D Cunningham, B Faissola, S Comitis, W Svensson, A Lim, R Williamson,
V Stewart
Imperial College Healthcare NHS Trust, London, UK
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Introduction: The term flat epithelial atypia (FEA) was introduced in 2003
by the WHO working group on the Pathology & Genetics committee of
tumours of the breast. Previously known as columnar cell change with
atypia, these lesions usually present as microcalcification and although there
is some evidence to suggest that FEA represents a precursor lesion in the
spectrum of low-grade breast neoplasia, there are limited data concerning
the ultimate clinical impact and optimum management strategy. The aim of
this study was to determine the radiological characteristics of FEA and final
histology following surgical excision at our centre.
Methods: Retrospective review of 950 consecutive image-guided core and
vacuum biopsies performed over an 8-year period revealed 162 lesions with
FEA as the most prominent pathologic entity; concomitant lobular neoplasia,
ADH or malignancies were excluded. The radiologic characteristics of FEA/
CCC lesions were assessed with respect to size, morphology and multifocality
at presentation. Biopsy technique and final histology of these lesions
following surgical excision were recorded.
Results: The rate of upgrade to a more significant pathology was 10%
(on provisional data, complete results will be presented) with significant
pathology being DCIS of varying grade. Microcalcification was the most
common mammographic sign.
Conclusion: Surgical excision of FEA at our centre has resulted in a low rate
of upgrade to malignancy supporting current thinking that some lesions
may be managed by vacuum excision, thus reducing the surgical diagnostic
excision rate.
P28
PB.28: Is second-time vacuum-assisted biopsy effective in improving
preoperative diagnosis rate of screen-detected DCIS?
S Pattison*, A Kumar, W Teh, R Patel
NLBSS, Edgware, UK
Breast Cancer Research 2013, 15(Suppl 1):P28
Introduction: The NHSBSP standards for non-operative diagnosis are a
target of 95% for invasive cancers (minimum 90%) and 90% for non-invasive
cancer (minimum 85%). The lower target for non-invasive cancers reflects the
difficulty in achieving definitive diagnosis of DCIS. Our unit has routinely used
vacuum biopsies (VAB) for non-operative diagnosis of microcalcifications.
Following an audit in 2009, repeat VAB were extended to B3 cases selected
in MDT in order to improve non-operative diagnosis of DCIS.
Methods: KC 62 report was used to identify all screen-detected cancers in
2011 and 2012. The mammographic characteristics, type and number
of biopsy procedures and results were reviewed and correlated against final
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surgical outcomes. A final outcome of LCIS was excluded from the audit.
The results were compared against a similar audit in 2008 and 2009.
Results: In total, 86/330 (26.1%) were DCIS. A total of 90.7% (78/86) of non-
invasive cancers were diagnosed preoperatively compared with 86% in 2008
and 2009. Non-operative diagnosis was achieved in 81.4% (70/86) on
the first biopsy and 9.3% (8/86) on the second biopsy. Four cases of DCIS
were completely excised by VAB. Six cases upgraded by repeat VAB were
microcalcifications. Seven of eight cases of DCIS with no preoperative
diagnosis were not subjected to second-time VAB.
Conclusion: Second-time VAB successfully improve non-operative
diagnosis of DCIS even when VAB are routinely used in the assessment of
microcalcifications. The practice should be considered for all B3 cases in
order to further improve the non-operative diagnosis rate for DCIS.
P29
PB.29: Ultrasound-guided vacuum-assisted percutaneous excision of
breast papillomas: results of long-term follow-up
AJ Maxwell1,2*, G Mataka1,3, S Whiteside4
1Royal Bolton Hospital, Bolton, UK; 2Nightingale Centre and Genesis
Prevention Centre, University Hospital of South Manchester, UK; 3Breast Unit,
Royal Lancaster Infirmary, Lancaster, UK; 4Department of Medical Statistics,
University Hospital of South Manchester, UK
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Introduction: The purpose was to determine the frequency of recurrent/
residual papillomas in women who had previously undergone vacuum-
assisted excision biopsy (VAB) of benign papillomas without atypia and to
identify factors that may be associated with recurrence.
Methods: Women who had undergone VAB of papillomas and had
subsequent breast imaging were identified from hospital records. Papilloma
size, VAB device used and number of cores was recorded and subsequent
imaging reviewed. Possible associations between the likelihood of recurrent/
residual papilloma and patient age, lesion size and excised volume to
papilloma volume ratio were analysed using Mann-Whitney U tests.
Results: Thirty-four women had subsequent imaging available. Median
follow-up was 1,052 days. Twelve women (35%) had evidence of a mass at
the excision site, with a median time to identification of recurrent/residual
papilloma of 1,369 days. In three of the six cases that underwent ultrasound
the recurrence was larger than the original lesion. Three recurrences were
removed at open surgical biopsy and one by further VAB. None of the 34
women were diagnosed with atypia or malignancy during follow up. No
significant association was found between the risk of recurrence and the
age of the patient, the size of the initial lesion or the ratio of the volume of
tissue removed to the lesion volume.
Conclusion: Recurrent/residual papillomas are common but most do not
require further intervention. No definite risk factors were identified. VAB
remains the excision method of choice for most benign papillomas without
atypia.
P30
PB.30: What is your biopsy threshold in symptomatic clinic and what
should it be? B2:B5 biopsy ratio: 18 months in our centre
R Gray*, G Porter, J Steel
Plymouth Hospitals NHS Trust, Plymouth, UK
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Introduction: While a <2% benign biopsy rate is widely regarded as the
gold standard in the screening population, there is no such guidance for
biopsy in symptomatic patients. When symptomatic patients present with
a lump visible on ultrasound, the decision to biopsy is down to the
individual radiologist. There is currently no gold standard for the benign:
malignant biopsy ratio.
Methods: A prospective list of all symptomatic clinic biopsies was
compiled over 18 months from January 2012 to May 2013. Imager and
histological outcome of each biopsy (B1 to B5) were recorded. Cancer
detection rate for each operator per 1,000 symptomatic cases was also
calculated. Axillary biopsies were excluded.
Results: Six anonymised operator biopsy results were recorded. There is a
wide variation with our centre of B2:B5 ratios without significant variation
in the cancer detection rate between operators.
Conclusion: This study demonstrates considerable variation in biopsy
threshold within one unit. There is no correlation of biopsy rate and cancer
detection in this dataset, meaning that potentially there are many
unnecessary biopsies performed. This study has stimulated discussion in our
unit, and is a useful and simple audit to perform to investigate biopsy
threshold. If performed by a number of units nationally, it may be possible
to assess the range for these parameters and to suggest a normal range.
P31
PB.31: B3 lesions and vacuum-assisted biopsy: a national survey to
gauge current practice
CL Strachan*, A Shaaban, K Horgan, N Sharma
St James University Hospital, Leeds, UK
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Introduction: Breast screening detects asymptomatic abnormalities which
occasionally on biopsy are classified indeterminate (B3). Such lesions have
malignant potential and traditionally are subject to open diagnostic excision
biopsy. Vacuum-assisted biopsy (VAB) offers larger representative tissue
sampling, and may act as a therapeutic measure completely excising the
lesion. The use of VAB in the NHSBSP varies widely. Currently there are no
relevant national guidelines to streamline practice.
Methods: A survey was sent to 80 screening units throughout England,
comprising seven questions concerning the use of VAB for B3 lesions.
Results: Fifty-four responses (67.5%) were received. Twenty-two per cent of
units do not perform VAB, 55% perform first-line and 77.8% second-line
VAB. For B3 lesions without atypia, 68% would proceed to second-line VAB
whilst 25% advocate open diagnostic excision following initial (14G) core.
Management of B3 lesions with atypia was more discordant, with the
majority of units opting for second-line VAB for FEA, ALH and LCIS, and
second-line diagnostic excision for radial scars, ADH (atypical intraductal
proliferation) and papillomas with atypia. Following first-line VAB, most units
would proceed to diagnostic excision rather than second-line VAB.
Conclusion: Management of B3 lesions varies significantly across
screening units. There is no concordance in the use of VAB for diagnosis or
management of B3 lesions. Whilst there is a trend toward second-line VAB
for atypias, significant numbers still opt for diagnostic excision. Consensual
national guidelines to standardise and guide management would provide
equity of care for this difficult management entity.
P32
PB.32: Does vacuum-assisted biopsy decrease the B3 rate in
stereotactic biopsy of breast lesions?
T Seaton*, S Khan, V Stewart, G Ralliegh, N Zaman, N Barrett, S Comitis,
A Gupta, W Svensson, A Lim, R Williamson, D Cunningham
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Introduction: Vacuum-assisted biopsy (VAB) systems have been shown to
outperform 14G core needle biopsy (CNB) reducing the need for diagnostic
or multiple surgeries. We introduced VAB in 2011 with the aim of reducing
our B3 rate and increasing rate of preoperative diagnosis of invasive cancer.
Methods: Mammographic abnormalities requiring stereotactic biopsy in a
defined period which had either 14G CNB or VAB were included. Data
collated included mammographic findings, biopsy and surgical outcome.
Results: Ninety 14G-CNBs (November 2010 to May 2011) were compared
with 78 VABS (July 2012 to January 2013). There was no reduction in our B3
rate (12 and 13 cases respectively) although VAB had higher sensitivity with
better correlation between biopsy diagnosis and surgical histology (77%
compared with 42%). Four of 12 (25%) B3 lesions diagnosed following 14G
CNB were upgraded to DCIS following surgical excision compared with no
cases following VAB. Preoperative invasive malignancy diagnostic rates were
unchanged, 15% of cases were upgraded in both groups.
Conclusion: VAB has not reduced our B3 rate but has increased the
accuracy of our preoperative diagnosis of non-invasive cancer supporting
current theories that patients who have undergone vacuum-assisted
biopsy may not require surgical diagnostic excision. However, we
recognise the number of cases is low and further cases will be analysed
and presented.
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Introduction: Increasing evidence supports vacuum-assisted biopsy (VAB)
instead of surgical excision for the management of lesions of uncertain
malignant potential (B3). This followed reports of up to 34% upgrade to
malignancy on excision. In January 2012, regional guidance was adopted to
clarify the options for managing such lesions. In our department, we have
used similar local guidelines since 2011. We report our analysis of the
management of B3 lesions before and after the introduction of VAB.
Methods: All B3 lesions were identified retrospectively, using our screening
database, before (1 January 2008 to 31 December 2009) and after (1 January
2011 to 31 December 2012) VAB use. Final pathological diagnosis following
surgical excision or VAB was recorded for both groups. The findings of
annual surveillance mammography were also recorded for lesions which
remained B3 but were radiologically excised following VAB.
Results: Before the use of VAB there were 94 B3 lesions, 80 (85%) of which
underwent surgical excision. After the use of VAB there were 85 B3 lesions,
of which 17 (20%) went on to have diagnostic surgery. The percentage of
upgrade to malignancy following further sampling was equal in both
groups, at 18%. Sixteen of 26 lesions, which remained B3 following VAB
excision, had surveillance mammography, none of which demonstrated
suspicious findings.
Conclusion: Our study provides further evidence that VAB is a safe
alternative to surgery for the management of B3 lesions, with identical
upgrade rates and reassuring follow-up results, following its use in our
department.
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Introduction: Patients undergoing breast biopsy are usually asked to return
to the results clinic, to enable face-to-face counselling and support.
However, a significant proportion of biopsies yield benign or normal results.
Since 2011 we have offered the choice of results by letter to selected
patients undergoing breast biopsy. This is at the discretion of the assessing
radiologist or surgeon, and includes radiologically guided biopsy of benign/
probably benign lesions and clinical biopsies where the imaging is normal.
Our aim was to identify our accuracy in assessing a patient as suitable for
results by letter.
Methods: Retrospective review of 100 consecutive patients entering this
pathway between January and May 2013. Patients were identified from MDT
lists, and hospital RIS and pathology systems were interrogated.
Results: One hundred females, age range 20 to 79 years (mean 42), were
included. Eighty-nine presented symptomatically, 11 were recalled from
screening. Ninety-two core biopsies and eight fine needle aspirates (FNAs)
were performed under ultrasound guidance (91 patients), stereotactically
(two patients) or freehand (seven patients with normal imaging). Cytology/
histology was normal or benign in 98 patients. Two patients were recalled
following FNA results of C4 and C5 and were subsequently diagnosed with
DCIS and invasive cancer, respectively.
Conclusion: Our current practice of identifying low-risk patients is 98%
accurate. Sending selected results by letter can obviate the need for a
results clinic appointment, with benefits to both patients and staff. However,
a robust method of tracking these patients is vital, as well as thorough MDT
discussion.
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Introduction: B3 lesion management is unclear. Despite varying malignancy
risk, diagnostic excision was conventional, revealing malignancy in some and
benign features in others. Large-bore vacuum-assisted biopsy (VAB, 7 to 8G)
can enhance pathological certainty, providing reassurance of benignity, or
identify co-existing malignancy, with many groups moving towards VAB to
replace surgical excision biopsy. However, little research has addressed the
accuracy of VAB compared with surgical biopsy in this situation.
Methods: From November 2011 to May 2013, we incorporated VAB into the
management of all B3 lesions identified by 10/14G biopsy. Excision biopsy
was still performed on any lesion initially identified as B3 with atypia, unless
upgraded by VAB. The VAB result and surgical excision outcomes were
compared.
Results: A total of 181 lesions were identified and considered for VAB.
Atypia was present in 102 lesions. Sixty-five of 102 lesions had VAB, with 11
upgraded to malignancy. Of the 54/65 lesions not upgraded by VAB, 25
proceeded to excision biopsy, revealing DCIS in seven. A total 37/102 lesions
did not have VAB (fibro-epithelial lesions/technical factors); malignancy was
identified in five at excision biopsy. The overall malignancy rate was 23/102
(22.5%). Of VAB/excision biopsy discordant lesions, average tissue obtained
at VAB was 2.4 g, compared with 2.9 g in concordant lesions (NS).
Conclusion: VAB can increase preoperative detection of malignancy, but
has an associated miss rate. Thirty per cent of the DCIS present in B3 lesions
with atypia was missed by second-line VAB. This is important to appreciate
as women are placed on surveillance programmes for B3 lesions following
VAB, but without completion excision biopsy.
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Introduction: There are currently no available guidelines regarding the
double reporting of patients discharged from the assessment clinic back to
the screening programme.
Methods: A retrospective audit of patients who were referred for arbitration
following discordant double reporting of patients discharged from the
assessment clinic was performed. This was performed over a 2-year period
from May 2011 to May 2013. The available imaging was reviewed. The
outcome of arbitration was documented. The morphology of the lesion,
whether a second assessment was required and outcome of the second
assessment were also recorded.
Results: A total of 4,445 patients were assessed in our breast unit. All
patients discharged back to the screening programme following
assessment were double reported at the end of the clinic. Thirteen (0.29%)
patients were referred for arbitration. The morphology of the lesions was
as follows: asymmetric density (n = 8), microcalcification (n = 4) and
distortion (n = 1). Following arbitration, nine patients were discharged
back to the screening programme. The remaining four patients underwent
a second assessment. All patients who underwent a second assessment
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had a biopsy performed. Three of these patients were discharged following
a benign biopsy result. The remaining patient was diagnosed with a grade
I invasive ductal carcinoma.
Conclusion: The number of patients requiring a second assessment is very
small (0.09%), limiting the psychological impact on our patients. Asymmetric
densities are the most common abnormality resulting in referral for
arbitration. Double reporting of assessment clinic patients discharged back
to the screening programme is now standard practice in our unit.
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Introduction: Ultrasound has long been used in the symptomatic service,
not only to distinguish cystic from solid masses but also to help in the
differentiation of benign from malignant lesions. The ability to correlate a
benign ultrasound mass with a mammographic mass eliminates the need
for further intervention. We evaluate the need for stereotactic biopsy in
screen-detected, nonpalpable lesions without calcification, which have either
benign or normal sonographic findings.
Methods: Patients who had stereotactic biopsy for mammographic lesions
from January 2011 to January 2013 were retrospectively identified from our
screening database. Clinical examination and ultrasound findings, presence
of calcification and pathological diagnosis were recorded. Final imaging
opinion was also recorded from the pathology request forms.
Results: Of 4,339 patients recalled for assessment, 1,860 had a biopsy (853
stereotactic and 1,007 ultrasound guided). Stereotactic biopsies were for
microcalcification (n = 748) and for 105 impalpable, noncalcified densities
with normal (n = 73) or benign (n = 32) ultrasound findings. Malignancy was
detected in eight (8%) noncalcified lesions and 169 (23%) microcalcifications
(P < 0.0002, Fischer exact test). Simple cysts were detected in 28/32 (88%) of
cases with benign ultrasound findings. Suspicion of malignancy was
mentioned in 38/105 (36%) final imaging opinions. Asymmetry (n = 4) and
distortion (n = 2) were the commonest lesion features associated with a
positive biopsy result.
Conclusion: Stereotactic biopsy for screen-detected mammographic
densities with normal or benign ultrasound findings has a low yield of
malignancy. Careful analysis of mammographic findings, ultrasound
correlation and further multidisciplinary discussion could help reduce
unnecessary biopsies.
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Introduction: The Marmot Review showed that although breast screening
saves lives, it is harmful through overdiagnosis - treating cancers that
would not otherwise have ever become clinically apparent. Currently, there
is no size threshold for recalling screening patients with calcifications. Our
aim was to assess whether a minimum size threshold would reduce
overdiagnosis.
Methods: We conducted a retrospective review of 375 screening patients
with microcalcifications over 24 months. We assessed all patients with pure
calcifications ≤10 mm documenting core biopsy, final histology and
treatment.
Results: Sixty-one cases of microcalcifications ≤10 mm: eight benign, 40
in situ cancers and 13 invasive cancers. This group was subcategorised into
calcifications: 0 ≤5 mm (24 patients) and 5 ≤10 mm (37 patients). In the 0
≤5 mm group, there were 16 in situ (low-grade, one; intermediate grade,
seven; high grade, eight) and two invasive cancers (G2 ductals ER/PR+Her2-
node-negative). In the 5 ≤10 mm group, there were 24 in situ (low-grade,
three; intermediate grade, 12; high grade, nine) and 11 invasive cancers
(four G1ER+Her2- node-negative, six G2ER+Her2-, one triple-negative).
One of these six cases was node-positive (micrometastasis) and one
G3ERPR+Her2- node-negative. All underwent wide local excision, and all
but one patient with invasive carcinoma received radiotherapy.
Conclusion: Recalling focal clusters of microcalcifications (<10 mm)
identified a high rate of cancers: 66% (40/61) in situ and 21% (13/61)
invasive. With regards to overdiagnosis: 51% (27/53) of cancers were low/
intermediate-grade DCIS or G1 invasive and 49% (26/53) were high-grade
DCIS or invasive G2/3. Therefore size is not a key factor in reducing
overdiagnosis.
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Introduction: In 2007, the Cancer Reform Strategy announced an extension
to the NHS Breast Screening Programme (NHSBSP) from women aged 50 to
70 to those 47 to 73 years. Pilot studies involved a 50% randomised cohort
at either the upper or lower end of the extension. We detail how our BSU
has instigated the complete lower age extension largely within existing
capacity.
Methods: Data collection from NBSS. Working practices identified from
local policy.
Results: Screening numbers increased from 22,022 to 26,272 (a 19%
increase), generating an extra 355.2 screening hours. This constituted a 76%
invite uptake in women aged 47 to 49. Screening appointments were
reduced from 6 to 5 minutes. Mammographers working patterns - but not
overall hours - were changed. An extra workstation was purchased for
additional film reading by existing personnel. All assessment clinics became
fully booked sessions (recall rate 9.4%). Biopsies were largely undertaken in
existing capacity but provision was increased when needed by altering staff
working patterns. Women requiring MDT discussion led to a marginal
increase in MDT length. All biopsy results were delivered by breast care
nurses - the extra work load required an additional session (4 hours) to fulfil
the demand. All screening targets were met.
Conclusion: Full lower end age extension has undoubtedly increased our
screening work load. However, by reducing the screening appointment
time, altering working patterns and purchasing a single extra workstation,
the impact to the service has been minimised. Potential difficulties do arise
in the event of sickness or leave.
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Introduction: Women with normal mammograms may be recalled from the
NHSBSP if they indicate significant clinical symptoms at the time of
screening. It is important that mechanisms are in place to record clinical
abnormalities, with a clear written protocol.
Methods: The Cambridgeshire screening population was examined from
April 2009 to April 2012. Our standard was that all patients with clinical
symptoms should have a clinical alert on NBSS, in keeping with 2005
assessment guidelines [1]. We analysed the number of women who were
clinically recalled for this period, if a clinical alert was entered on NBSS, the
symptoms underlying the clinical recall, and the clinical outcome.
Results: A total of 50,785 patients were screened, of which 165 with normal
mammography were placed on clinical recall. In total, 151 (92%) had a
clinical alert on NBSS. Thirty-seven of these had an abnormality detected, of
which the majority (n = 17) were cysts. Four (2% or 0.8 per 10,000 screened)
had an invasive malignancy. A palpable lump was the commonest clinical
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symptom for recall, but also included nipple discharge, pain and patient
anxiety.
Conclusion: Electronic NBSS documentation for clinical recall is an
important measure to ensure patients with normal mammograms but
clinically significant symptoms are not returned to routine screening.
Radiographers should receive appropriate training to recognise significant
breast symptoms, with a clear written protocol for clinical recall. New local
guidelines have been implemented prior to re-audit.
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Introduction: Discordant breast cancers are identified following differing
interpretations on double-read screening mammograms. The aim of this
audit was to analyse the mammographic features of discordant breast
cancers to improve reader sensitivity.
Methods: The screening programme database was used to identify all
breast cancers that were diagnosed from 1 April 2010 to 31 March 2012.
Discordant cases were reviewed at a consensus meeting in which the
mammographic sign, size, site, parenchymal pattern and final histology were
recorded.
Results: Fifty-seven of a total of 670 cancers had discordant reads. The most
common mammographic abnormality was spiculated masses (30%).
Microcalcifications accounted for 25% of cases. Eighty-five per cent of the
abnormalities were small (i.e. ≤15 mm). No single view was noted to be
more likely to reveal the abnormality. The histology results showed no
difference in distribution of tumour type compared with nondiscordant
tumours. The second reader identified 69% of the discordant cancers.
Conclusion: A total 8.5% of the screen-detected cancers in this audit
were discordant-read cancers, which corresponds with published findings
[1]. The mammographic features of discordant cancers were similar to
nondiscordant cancers. The study supports the continued use of two
readers to maximise sensitivity [2].
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Introduction: It is important to keep recall rates to a minimum. At the Jarvis
Centre daily arbitration is performed by two experienced film readers, a
regular pair each weekday. Observation that different arbitration pairs have
varying thresholds for recalling round masses prompted this audit.
Methods: Thirty-six digital cases with round masses were selected during
arbitration over a 1-month period. All cases were anonymised and re-
arbitrated by six pairs of arbitrators who usually work together. The pairs
included at least one film reader with over 10 years experience. Specific
mammographic features and the final audit recall decision were recorded.
Results: A total 17/36 (47%) cases were recalled at the original arbitration.
Arbitration pairs had different audit recall rates ranging from 39 to 81%. All
arbitrators agreed to either rescreen or recall in 1/3 of cases. Results
showed there was variation in both perception of mammographic features
present and the importance given to other factors such as age, multiplicity,
lesion location and density; affecting recall even in the presence of benign
mammographic features.
Conclusion: There is considerable variation in opinion between arbitration
pairs due to the complex nature of interpreting which mammographic
features are present and balancing these against other factors such as age,
multiplicity, lesion location, and density. It is useful to reflect on the steps
in the decision-making process to understand the science behind the art
in an attempt to achieve more consistency between pairs and keep recall
rates down.
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Introduction: The aim of National Health Services Breast Screening
Programme (NHSBSP) is to reduce morbidity and mortality related to breast
cancer. The success of NHSBSP depends upon a high proportion of women
attending for their 3-yearly screening mammograms. The national target for
screening attendance is 80% and the minimum standard is 70%. For 2010
and 2011, an overall national screening uptake for women aged 50 to 70
was 73.4%. The overall uptake rate for our screening service is recorded as
the fifth lowest in achieving minimum uptake targets. The purpose of this
review was to analyse the factors associated with poor uptake in some of
our screening regions and assess the effectiveness of the methods used to
maximise attendance in these regions.
Methods: The source of our data collection was west Midlands Cancer
Intelligence Unit and NHSBSP database. We analysed the trends in
screening uptake from 2007 to 2013.
Results: Social deprivation, population size, ethnicity, availability and access,
and education and awareness are some of the most significant factors that
affect uptake. Interventions were devised to target these factors. The
initiatives used were simple such as patient letters, promotional posters and
multi-lingual leaflets, DNA flyers, telephonic reminders and most importantly
collaborative work with GP surgeries. The results were encouraging and we
managed to increase the prevalent uptake by 7.87% in our lowest uptake
region.
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Introduction: A total of 267 women screened by the family history clinic
(FHC) have been diagnosed with breast cancer since 1990. In 73 women the
cancers were diagnosed in the interval between mammographic screens,
which were performed every 1 to 2 years and single read. The aim of this
audit was to compare performance with that of the NHS Breast Screening
Programme (NHSBSP).
Methods: Screening mammograms were found for 21 women, who had
22 interval cancers (one was bilateral). Thirteen had symptomatic
mammograms available for comparison. The site of the cancer was known
for eight of the remaining nine cases. Blinded review of the screening
mammograms was performed and then comparison was made with the
symptomatic mammograms or other available location data.
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Results: The screening mammograms were classified as follows: Category 0
(no symptomatic mammograms available), 9; Category 1 (screening
mammograms normal), 7; Category 2A (subtle appearances, recall not
justified), 2; Category 2B (subtle appearances, recall indicated), 2; and
Category 3 (suspicious abnormality), 2. Of the eight Category 0 cases with a
known tumour location, a subtle abnormality was visible in this area in one
case but the remainder were normal. Thus the screening mammograms
were normal in 14 of the 21 cases (67%) where the tumour location was
known. Fifteen (68%) of the interval cancers were diagnosed within 12
months of the last mammogram.
Conclusion: The proportion of Category 2 and 3 cases is similar to that
seen in the NHSBSP. Double reading may reduce the number of these in the
FHC population.
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Introduction: NICE Clinical Guidelines recommend that young women at
high risk of breast cancer are offered annual surveillance with MRI and
digital mammography. A feasibility study was run over 3 years (2010 to
2013) for women with known BRCA1 or BRCA2 mutations and those with, or
at high risk of, a TP53 gene mutation. We aimed to explore the practicalities
of delivering a surveillance service for these high-risk women.
Method: Eligible women were identified by the All-Wales Medical Genetics
Service and offered annual MRI, with digital mammography where
appropriate, at three centres across Wales. Administration was managed by
Breast Test Wales.
Results: Qualitative feedback showed that women were willing to travel for
appointments and the service was acceptable. Only 12 of the 38 participants
attended all years. This is a dynamic group - some develop cancer, others opt
for risk-reducing surgery, and each year some were ineligible as they were
pregnant or breastfeeding. Administration of the system was complex,
involving different professional groups working across sites. Standards for
waiting times for results were not met. Few radiologists in Wales meet the
English standard of 100 breast MRI examinations per year to be eligible as
readers. This poses a challenge for service delivery. MRI scanner capacity is
also limited.
Conclusion: The enthusiasm of the multidisciplinary team ensured the
project was successful and the service delivered. However, there were major
administrative and resource challenges, and the pilot service model was
unsustainable. The evaluation will be used to inform decisions on future
service provision.
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Introduction: Peutz-Jeghers Syndrome (PJS) is a rare autosomal dominantly
inherited polyposis syndrome caused by STK11 germline mutation. PJS is
characterised by gastrointestinal polyps and mucocutaneous pigmentation.
These patients have an increased risk of developing cancers, luminal
gastrointestinal cancers and breast cancer being the most common, then
pancreatic cancer [1,2].
Methods: A retrospective review of a prospectively maintained database at
a tertiary referral centre was carried out. A total of 136 patients from 92
families were included.
Results: The median age when patients were first seen was 20 years (range,
2 to 65). Twenty-seven carcinomas were detected in 19 patients; 15 were
carcinoma of the breast (55%) (two patients had bilateral disease). All of the
breast cancers were in women and were predominantly ductal carcinoma
in situ. Of the 13 patients with breast cancer, a STK11 mutation was
detected in eight (62%).
Conclusion: The cumulative risk of developing breast cancer is 31 to 54% at
age 60 years, with a median age at diagnosis of 37 years (range, 19 to
48 years) in PJS patients [3]. Published European guidelines recommend
annual magnetic resonance imaging of the breast from age 25 to 30 years,
with mammography being substituted after age 50 years [3], which we
endorse.
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Introduction: Until recently, in our institution, all women over the age of
35 years referred to the symptomatic breast clinic for triple assessment
undergo mammography. Best practice diagnostic guidelines for patients
presenting with breast symptoms (Department of Health November 2010)
recommend that mammograms should routinely be performed in women
aged over 40 years. The aim of this study was to assess the impact that
changing our policy would have on breast cancer detection in women aged
35 to 39 years.
Methods: Our Breast Cancer Database identified all women aged 35 to 39
years diagnosed with breast cancer between April 2003 and December
2012. A retrospective review of breast imaging and reports on PACS was
carried out to determine whether ultrasound alone would have detected the
malignancy.
Results: 106 cancers were diagnosed in 103 women aged 35-39 years. In
103 cases, ultrasound scores using the RCR Breast Group Classification
ranged from U3 (indeterminate/probably benign) to U5 (highly suspicious of
malignancy). Two patients presented with nipple discharge. One of these
patients had mammographic microcalcification due to extensive DCIS with
small separate foci of invasive cancer with normal ultrasound examination.
Conclusion: In our institution, one case of extensive DCIS with small
separate foci of invasive cancer out of a total of 106 breast cancers would
have been missed on breast imaging if routine mammography had not
been performed in women aged 35-39 years.
P48
PB.48: Old habits die hard: breast imaging of symptomatic 35 to
39 year olds
FM Singh*, S Gadde
Nightingale Centre and Genesis Prevention Centre, University Hospital of
South Manchester NHS Foundation Trust, Wythenshawe, Manchester, UK
Breast Cancer Research 2013, 15(Suppl 1):P48
Introduction: The Best Practice Diagnostic Guidelines for Patients Presenting
with Breast Symptoms were published in 2010 and suggest patients younger
than 40 years should undergo breast ultrasound (US) as first-line imaging,
with additional mammography for indeterminate and suspicious clinical or
US findings. However, our current departmental guidelines are to use first-
line mammography in patients aged 35 and over. The aims were to quantify
the use of imaging modalities and cancer detection; to assess whether
additional information gained by mammography changed management;
and to quantify how many fewer mammograms would have been
performed if we had adhered to the 2010 Guidelines.
Methods: Imaging and histology reports were reviewed over a 6-month
period for 35-year-old to 39-year-old females with a symptomatic breast
complaint.
Results: A total of 247 symptomatic 35 to 39 year olds had breast imaging
with a malignancy rate of 4%, all cancers presented with a lump/thickening.
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Sixty-nine per cent had both US and mammography, 23% mammography
only and 9% US only. Four U3 lesions were detected on US with normal
mammograms, one of which was malignant. Mammography altered
management in three patients, requiring biopsies of the asymptomatic
breast, none of which were malignant. If we had adhered to the 2010
Guidelines we would have performed 150 fewer mammograms out of the
171 patients who had both US and mammography.
Conclusion: In our study, no malignancy would have been missed and we
would have performed 150 fewer mammograms if we had adhered to the
2010 Guidelines and used US as a first-line investigation.
P49
PB.49: Preoperative axillary staging in breast cancer patients: repeat
sampling in cases of suspicious ultrasound or inconclusive cytology
L Clarke*, P Newton, A Leaver
Queen Elizabeth Hospital, Gateshead, UK
Breast Cancer Research 2013, 15(Suppl 1):P49
Introduction: In our Trust preoperative axillary staging comprises
ultrasound with appearances scored LN1 to LN5, and fine needle aspiration
(FNA) of LN3 to LN5 nodes. Repeat sampling with FNA or core biopsy (CB) is
performed on inconclusive FNA (C1, C3, C4) at the discretion of the
radiologist. Repeat sampling is also performed in LN4/5 C2 patients. There
has been a trend toward the more invasive and expensive CB for repeat
axillary sampling in our unit. Here we assess our practice and the diagnostic
yield from repeat sampling, to review current departmental guidelines.
Method: All invasive breast cancer patients who underwent surgery in 2012
were identified from multidisciplinary meeting records. Cytology and
histology reports from repeat preoperative sampling and surgery were
reviewed.
Results: In 2012, 169 female breast cancer patients underwent axillary FNA
and axillary surgery. FNA was followed by CB in 26% (44/169) and no FNAs.
Of C1/C3/C4 FNAs, 34/39 had CB. Of these, 10/34 were malignant. CB was
negative in 23, with 20/23 negative nodes and 3/23 positive nodes at
surgery. There were 79 C2 FNAs with 10/79 undergoing CB. Nine of 10 cores
were negative, of which one was node-positive at surgery. The 1/10 positive
core represented micrometastasis on clearance. No complications resulted
from axillary FNA or CB.
Conclusion: Repeat biopsy including CB is useful in C1/C3/C4 cytology,
improving triage to the correct axillary surgical procedure. Repeat biopsy of
C2 nodes with LN4/5 ultrasound has not been validated here: ongoing audit
and a higher threshold for repeat biopsy in these patients should be
considered.
P50
PB.50: Axillary lymph node ultrasound in breast cancer patients: what
minimum threshold for diffuse cortical thickening predicts nodal
involvement?
L Clarke*, A Leaver, P Newton
The Queen Elizabeth Hospital, Gateshead, UK
Breast Cancer Research 2013, 15(Suppl 1):P50
Introduction: In our Trust we classify axillary ultrasound findings as LN1 to
LN5, performing fine needle aspiration cytology (FNAC) on LN3 to LN5,
where LN3 represents diffuse cortical thickening (DCT) of greater than
2 mm. The resulting FNAC triages patients to either sentinel lymph node
biopsy or axillary node dissection. The aim is that patients will undergo only
one axillary surgical procedure. There is variation in the literature and
between breast units in the DCT threshold for performing FNA, and
unnecessary FNAs should be avoided. Does the resulting cytology and
surgical histology validate our 2 mm threshold; or can the threshold be
safely increased to 2.3 mm or 3 mm as used by some centres?
Methods: The MDT records and images for all our invasive breast cancer
patients classified axillary LN3 and operated upon in 2012 were reviewed.
The positive predictive value (PPV) was calculated for ranges of DCT for a
post-test probability of a C5 result at FNA, and then for the yield of 2+
positive nodes at surgery.
Results: A total of 112 female patients were LN3 and underwent FNA in
2012. The PPV for a C5 result in DCT in ranges 2.0 to 2.29, 2.30 to 2.99 and
≥3.0 was 9.1% (1/11), 11.3% (6/53) and 14.6% (7/48) respectively. The PPV
for a yield of 2+ malignant nodes was 9.1% (1/11), 9.4% (5/53) and 4.2%
(2/48) respectively.
Conclusion: These findings have validated our use of the 2 mm threshold
for FNAC. Increasing the threshold would result in a significant number of
women requiring a second axillary surgical procedure as current treatment
guidelines stand.
P51
PB.51: Axillary lymph node ultrasound and fine needle aspiration in
preoperative staging of breast cancer: re-audit
H Kazi1*, H Humphreys2, L Clarke2, A Robinson2, A Leaver2
1South Tyneside Hospital, South Shields, UK; 2Queen Elizabeth Hospital,
Gateshead, UK
Breast Cancer Research 2013, 15(Suppl 1):P51
Introduction: Axillary ultrasound and fine needle aspiration (FNA) are used
to triage breast cancer patients to appropriate axillary surgery. We present a
complete audit cycle. Departmental guidelines were changed to include
repeat biopsy in cases with suspicious ultrasound/negative FNA and for
patients with inconclusive FNA results between audit periods one and two.
Methods: Retrospective analysis of multidisciplinary meeting and pathology
records of all breast cancer patients operated upon in our Trust between
January and June 2010, and then between January and December 2012,
was reviewed. Descriptive statistics were performed.
Results: Initial audit findings included 125 female patients, with overall
combined sensitivity and specificity of ultrasound/FNA being 64% (21/33)
and 100% (92/92) respectively. Included in the re-audit were 378 female
patients, all underwent axillary ultrasound. Of these, 50.3% (190/378)
patients underwent an FNA with 18.4% (35/190) having repeat FNA or core
biopsy for inconclusive results. Of the repeat biopsies, 80% (28/35) were
benign and 20% (7/35) were malignant. Ultrasound sensitivity was 78.9%
(86/109). Sensitivity of FNA/biopsy was 82.6% (71/86). Overall combined
sensitivity of ultrasound/FNA was 62.2% (74/119). Ultrasound specificity was
62.1% (167/269). Specificity of FNA was 97.1% (101/104). Overall combined
specificity of ultrasound/FNA was 98.9% (266/269).
Conclusion: Performing a repeat FNA/biopsy on inconclusive cases proved
valuable in that 80% patients were spared from surgical morbidity. However,
overall sensitivity of preoperative axillary staging has not significantly
changed between cycles following resampling. Further audit, analysis and
guideline review is needed to ensure optimal patient care.
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PB.52: Incidence and clinical significance of focal breast uptake at
18-fluorine fluorodeoxyglucose PET-CT in patients without
known breast cancer
P Arce-Calisaya*, J Simpson, N Sharma, A Scarsbrook
Saint James’s University Hospital, Leeds, UK
Breast Cancer Research 2013, 15(Suppl 1):P52
Introduction: 18-Fluorine fluorodeoxyglucose (FDG) PET-CT is a sensitive
technique and hypermetabolic foci unrelated to the primary malignancy are
not infrequently encountered. The aim of this study was to evaluate the
clinical significance of unexpected focal FDG uptake within the breast in
patients undergoing PET-CT for assessment of other malignancies.
Methods: Consecutive adult patients undergoing FDG PET-CT for
assessment of a nonbreast primary cancer between February 2009 and
October 2012 were retrospectively reviewed. The incidence of focal FDG
uptake within the breast was determined. PET parameters including
maximum standardised uptake value (SUVmax), metabolic tumour volume,
and total lesion glycolysis were recorded for each patient. The presence and
patterns of morphologic changes on CT were assessed. Aetiology and
clinical significance were confirmed histologically or by imaging and clinical
follow-up.
Results: A total 23 of 8,972 patients (0.25%) had unexpected focal FDG
uptake in the breast. Twenty patients (86%) underwent biopsy. Malignancy
was confirmed in 17 patients, five patients (22%) had disseminated disease
from their primary cancer and 12 patients (52%) had an unsuspected
synchronous breast cancer. Eight patients (67%) with newly diagnosed
breast cancer were outside the screening programme (≤47 ≥73 years). Only
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five patients (42%) had a breast lesion with SUVmax >4. No PET parameters
reliably distinguished benign from malignant pathology.
Conclusion: Incidental focal FDG uptake in the breast is rare but requires
further evaluation as approximately 50% of cases may reflect
unsuspected breast malignancy.
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PB.53: Are ethnic minorities more likely to develop triple-negative
breast cancer? A systematic review
R Limbada1*, A Slater1, AK Jain2
1De Montfort University, Leicester, UK; 2The Nightingale Centre and Genesis
Prevention Centre, Wythenshawe Hospital, Manchester, UK
Breast Cancer Research 2013, 15(Suppl 1):P53
Introduction: Triple-negative breast cancer (TNBC) accounts for 10 to
15% of diagnosed breast cancers worldwide. TNBC is negative for
oestrogen receptor, progesterone receptor and human epidermal growth
factor receptor 2 expression, and is associated with a poor prognosis. Our
study aims to systematically review the possible link between various
minority ethnic groups and development of TNBC.
Methods: A systematic review of carefully selected studies was carried out
with search of relevant articles in Medline, Science Direct and PubMed
from 2005 up to 2013 with studies specifically aimed at TNBC. In the UK,
receptor data have not been consistently recorded and involve smaller
sample sizes. Hence, the relevant articles include ethnic groups from Asia
Pacific and USA. Keywords were: triple negative, TNBC, ethnicity, incidence,
prevalence. The data from all relevant articles were combined to give a
sufficiently large sample size.
Results: Complete receptor data were available for 72,763 cases, which
constitute the sample group. On the available ethnicity data these were
divided into five groups: Caucasian (n = 50,797), Black (n = 4,969), Asian
(n = 6,909), Hispanic (n = 9,898) and other (n = 190). Overall there were
9,887 TNBC cases in the sample group with Caucasian (n = 5,956), Black
(n = 1,341), Asian (n = 842), Hispanic (n = 1,732) and other (n = 16).
Hence, overall 13.59% of all diagnosed breast cancers were TNBC with
11.73% in Caucasian, 26.99% in Black, 12.19% in Asian, 17.5% in Hispanic
and 8.42% in other women.
Conclusion: Overall minority ethnic women have higher incidence of
TNBC than Caucasian women with resultant poor prognosis. With rising
minority ethnic population in the UK the overall number of TNBC will
rise. Further research is required into the reasons for this.
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